Literature DB >> 10536743

Symptom provocation studies in psychiatric disorders: scientific value, risks, and future.

D C D'Souza1, R M Berman, J H Krystal, D S Charney.   

Abstract

Several lines of investigation have contributed to the increasing recognition of the biological basis of psychiatric disorders. Symptom provocation studies have made important contributions toward this. With the emergence of novel methodologies, the role of symptom provocation studies has come under increasing scrutiny and debate. The scientific contributions and risks of symptom provocation studies are discussed using the psychostimulant paradigm in schizophrenia research as the prototypical study. The application of studies in other areas of medicine that carry risks similar to those associated with symptom provocation studies, are also reviewed. The authors draw on the parallel of cardiac stress testing to highlight risks: benefits issues. Finally, the authors discuss the future of symptom provocation studies and emphasize that these studies will need to meet the highest scientific standards, ethical standards and safeguards.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10536743     DOI: 10.1016/s0006-3223(99)00209-7

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  8 in total

1.  A summary of important documents in the field of research ethics.

Authors:  Bernard A Fischer
Journal:  Schizophr Bull       Date:  2005-09-28       Impact factor: 9.306

Review 2.  Emerging empirical evidence on the ethics of schizophrenia research.

Authors:  Laura B Dunn; Philip J Candilis; Laura Weiss Roberts
Journal:  Schizophr Bull       Date:  2005-10-19       Impact factor: 9.306

3.  Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine.

Authors:  Hyun-Sang Cho; Deepak C D'Souza; Ralitza Gueorguieva; Edward B Perry; Steven Madonick; Laurence P Karper; Anissa Abi-Dargham; Aysenil Belger; Walid Abi-Saab; Deborah Lipschitz; Alexandre Bennet; John P Seibyl; John H Krystal
Journal:  Psychopharmacology (Berl)       Date:  2005-01-29       Impact factor: 4.530

4.  The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories.

Authors:  Michelle Carbuto; R Andrew Sewell; Ashley Williams; Kim Forselius-Bielen; Gabriel Braley; Jacqueline Elander; Brian Pittman; Ashley Schnakenberg; Savita Bhakta; Edward Perry; Mohini Ranganathan; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2011-08-16       Impact factor: 4.530

5.  Serotonergic responses in depressed patients with or without a history of alcohol use disorders and healthy controls.

Authors:  Leo Sher; Barbara H Stanley; Thomas B Cooper; Kevin M Malone; J John Mann; Maria A Oquendo
Journal:  Eur Neuropsychopharmacol       Date:  2008-06-30       Impact factor: 4.600

Review 6.  The early identification of psychosis: can lessons be learnt from cardiac stress testing?

Authors:  Swapnil Gupta; Mohini Ranganathan; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2015-11-14       Impact factor: 4.530

7.  Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis.

Authors:  Jörg Daumann; Karsten Heekeren; Anna Neukirch; Christiane M Thiel; Walter Möller-Hartmann; Euphrosyne Gouzoulis-Mayfrank
Journal:  Psychopharmacology (Berl)       Date:  2008-07-24       Impact factor: 4.530

8.  Human models as tools in the development of psychotropic drugs.

Authors:  Christian Gilles; Thérèse Schunck; Gilles Erb; Izzie Jacques Namer; Yann Hodé; Jean-François Nedelec; Peter Boeijinga; Remy Luthringer; Jean-Paul Mâcher
Journal:  Dialogues Clin Neurosci       Date:  2002-12       Impact factor: 5.986

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.